These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1747015)

  • 21. Neuroinflammation is increased in the parietal cortex of atypical Alzheimer's disease.
    Boon BDC; Hoozemans JJM; Lopuhaä B; Eigenhuis KN; Scheltens P; Kamphorst W; Rozemuller AJM; Bouwman FH
    J Neuroinflammation; 2018 May; 15(1):170. PubMed ID: 29843759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative differences in the deposition of beta A4 protein in the sulci and gyri of frontal and temporal isocortex in Alzheimer's disease.
    Gentleman SM; Allsop D; Bruton CJ; Jagoe R; Polak JM; Roberts GW
    Neurosci Lett; 1992 Feb; 136(1):27-30. PubMed ID: 1635663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regional distribution of TDP-43 inclusions in Alzheimer disease (AD) brains: their relation to AD common pathology.
    Kadokura A; Yamazaki T; Lemere CA; Takatama M; Okamoto K
    Neuropathology; 2009 Oct; 29(5):566-73. PubMed ID: 19422539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concentrations of several proteins characteristic of nervous tissue in cerebral cortex of patients with Alzheimer's disease.
    Kato K; Kurobe N; Suzuki F; Morishita R; Asano T; Sato T; Inagaki T
    J Mol Neurosci; 1991; 3(2):95-9. PubMed ID: 1814396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of pituitary adenylate cyclase-activating polypeptide with cognitive decline in mild cognitive impairment due to Alzheimer disease.
    Han P; Caselli RJ; Baxter L; Serrano G; Yin J; Beach TG; Reiman EM; Shi J
    JAMA Neurol; 2015 Mar; 72(3):333-9. PubMed ID: 25599520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics of neuronal lipofuscin in the superior temporal gyrus in Alzheimer's disease do not differ from non-diseased controls: a comparison with disease-related changes in the superior frontal gyrus.
    Mountjoy CQ; Dowson JH; Harrington C; Cairns MR; Wilton-Cox H
    Acta Neuropathol; 2005 May; 109(5):490-6. PubMed ID: 15759127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overlap between frontotemporal dementia and Alzheimer's disease: cerebrospinal fluid pattern and neuroimaging study.
    Padovani A; Premi E; Pilotto A; Gazzina S; Cosseddu M; Archetti S; Cancelli V; Paghera B; Borroni B
    J Alzheimers Dis; 2013; 36(1):49-55. PubMed ID: 23568100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic association of CDC2 with cerebrospinal fluid tau in Alzheimer's disease.
    Johansson A; Zetterberg H; Hampel H; Buerger K; Prince JA; Minthon L; Wahlund LO; Blennow K
    Dement Geriatr Cogn Disord; 2005; 20(6):367-74. PubMed ID: 16192727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease.
    Ossenkoppele R; Mattsson N; Teunissen CE; Barkhof F; Pijnenburg Y; Scheltens P; van der Flier WM; Rabinovici GD
    Neurobiol Aging; 2015 Aug; 36(8):2340-7. PubMed ID: 25990306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tau protein in the glial cytoplasmic inclusions of multiple system atrophy can be distinguished from abnormal tau in Alzheimer's disease.
    Cairns NJ; Atkinson PF; Hanger DP; Anderton BH; Daniel SE; Lantos PL
    Neurosci Lett; 1997 Jul; 230(1):49-52. PubMed ID: 9259461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TAU haplotype and the Saitohin Q7R gene polymorphism do not influence CSF Tau in Alzheimer's disease and are not associated with frontotemporal dementia or Parkinson's disease.
    Johansson A; Zetterberg H; Håkansson A; Nissbrandt H; Blennow K
    Neurodegener Dis; 2005; 2(1):28-35. PubMed ID: 16909000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele.
    Blennow K; Bogdanovic N; Alafuzoff I; Ekman R; Davidsson P
    J Neural Transm (Vienna); 1996; 103(5):603-18. PubMed ID: 8811505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer's disease.
    Lidström AM; Bogdanovic N; Hesse C; Volkman I; Davidsson P; Blennow K
    Exp Neurol; 1998 Dec; 154(2):511-21. PubMed ID: 9878186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies.
    Muntané G; Dalfó E; Martinez A; Ferrer I
    Neuroscience; 2008 Apr; 152(4):913-23. PubMed ID: 18343584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Localization of heparan sulfate glycosaminoglycan and proteoglycan core protein in aged brain and Alzheimer's disease.
    Su JH; Cummings BJ; Cotman CW
    Neuroscience; 1992 Dec; 51(4):801-13. PubMed ID: 1488123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Study of Aβ Oligomers in the Temporal Cortex and Cerebellum of Patients with Neuropathologically Confirmed Alzheimer's Disease Compared to Aged Controls.
    Savioz A; Giannakopoulos P; Herrmann FR; Klein WL; Kövari E; Bouras C; Giacobini E
    Neurodegener Dis; 2016; 16(5-6):398-406. PubMed ID: 27400224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tau protein immunoreactivity in dementia of the Alzheimer type: II. Electron microscopy and pathogenetic implications. Effects of fixation on the morphology of the Alzheimer's abnormal filaments.
    Papasozomenos SC
    Lab Invest; 1989 Mar; 60(3):375-89. PubMed ID: 2494388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo.
    Praticò D; MY Lee V; Trojanowski JQ; Rokach J; Fitzgerald GA
    FASEB J; 1998 Dec; 12(15):1777-83. PubMed ID: 9837868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heat-shock protein 70 levels in brain of patients with Down syndrome and Alzheimer's disease.
    Yoo BC; Seidl R; Cairns N; Lubec G
    J Neural Transm Suppl; 1999; 57():315-22. PubMed ID: 10666686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective changes of calcineurin (protein phosphatase 2B) activity in Alzheimer's disease cerebral cortex.
    Lian Q; Ladner CJ; Magnuson D; Lee JM
    Exp Neurol; 2001 Jan; 167(1):158-65. PubMed ID: 11161603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.